Key result
A theoretical gene therapy for rheumatoid arthritis, active only during joint inflammation, is proposed to prevent systemic side effects and improve patient quality of life.
Why the study?
Current treatment options for rheumatoid arthritis have serious limitations and merely offer short-term pain alleviation.
Proposes a theoretical gene therapy approach for rheumatoid arthritis that activates only during joint inflammation to minimize systemic side effects.
Rheumatoid Arthritis (RA) is an autoimmune and inflammatory disease that affects the synovium (lining that surrounds the joints), causing the immune system to attack its own healthy tissues. Treatment options, to the current day, have serious limitations and merely offer short-term alleviation to the pain. Using a theoretical exercise based on literature, a new potentially viable therapy has been proposed. The new therapy focusses on a long-term treatment of RA based on gene therapy, which is only active when inflammation of the joint occurs. This treatment will prevent side effects of systemic application of drugs. Furthermore, the benefits of this treatment for the patient from a socio-economic perspective has been discussed, focusing on the quality of life of the patent and lower costs for the society.
No takes yet. Share an insight, caveat, or question.
Tsitrouli et al. (2021) conducted a review in Rheumatoid Arthritis. Gene therapy was evaluated. A theoretical gene therapy for rheumatoid arthritis, active only during joint inflammation, is proposed to prevent systemic side effects and improve patient quality of life.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: